Exact Sciences (EXAS) Projected to Post Earnings on Monday

Exact Sciences (NASDAQ:EXAS) is projected to post its Q3 2025 results after the market closes on Monday, November 3rd. Analysts expect Exact Sciences to post earnings of $0.10 per share and revenue of $810.4160 million for the quarter. Individuals can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Monday, November 3, 2025 at 5:00 PM ET.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Wednesday, August 6th. The medical research company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.24. The firm had revenue of $811.09 million during the quarter, compared to the consensus estimate of $774.43 million. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The business’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.09) EPS. On average, analysts expect Exact Sciences to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Exact Sciences Stock Up 2.3%

Shares of Exact Sciences stock opened at $64.69 on Friday. The stock has a 50-day moving average price of $55.95 and a 200 day moving average price of $52.51. The company has a market cap of $12.25 billion, a P/E ratio of -11.91, a P/E/G ratio of 5.56 and a beta of 1.24. The company has a current ratio of 2.89, a quick ratio of 2.56 and a debt-to-equity ratio of 0.94. Exact Sciences has a 1 year low of $38.81 and a 1 year high of $72.83.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Royal Bank Of Canada reduced their price objective on Exact Sciences from $54.00 to $46.00 and set a “sector perform” rating for the company in a research note on Thursday, August 7th. Evercore ISI upped their target price on Exact Sciences from $64.00 to $68.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Craig Hallum upped their target price on Exact Sciences from $65.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, September 11th. Cowen reaffirmed a “buy” rating on shares of Exact Sciences in a research report on Thursday, August 7th. Finally, UBS Group dropped their target price on Exact Sciences from $61.00 to $53.00 and set a “neutral” rating on the stock in a research report on Thursday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Exact Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $68.90.

Insider Activity at Exact Sciences

In other news, Director James Edward Doyle sold 2,000 shares of the stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $60.00, for a total transaction of $120,000.00. Following the transaction, the director owned 57,962 shares of the company’s stock, valued at approximately $3,477,720. This represents a 3.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Geneos Wealth Management Inc. increased its holdings in shares of Exact Sciences by 68.6% during the 2nd quarter. Geneos Wealth Management Inc. now owns 1,915 shares of the medical research company’s stock valued at $102,000 after acquiring an additional 779 shares during the last quarter. Federated Hermes Inc. acquired a new position in shares of Exact Sciences during the 2nd quarter valued at about $126,000. EverSource Wealth Advisors LLC increased its holdings in shares of Exact Sciences by 206.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,204 shares of the medical research company’s stock valued at $170,000 after acquiring an additional 2,159 shares during the last quarter. Great Lakes Advisors LLC increased its holdings in shares of Exact Sciences by 3.7% during the 1st quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock valued at $215,000 after acquiring an additional 178 shares during the last quarter. Finally, IHT Wealth Management LLC acquired a new position in shares of Exact Sciences during the 2nd quarter valued at about $228,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.